43 completed, 13 recruiting, 6 unknown, 5 withdrawn. 72 Phase 2, 16 Phase 1, 11 Phase 3.
Follow Obstructive Sleep Apnea: new trials by email Literature Review of Obstructive Sleep Apnea trials Research Report on Obstructive Sleep Apnea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Of Synthetic THC And Sleep Dronabinol, Placebo - Obstructive Sleep Apnea | Phase 2 / Phase 3 | Not yet recruiting | Mayo Clinic | 72 | 2026-11-01 | 2026-09-18 |
| Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition - Obstructive Sleep Apnea, Sleep-disordered Breathing | Phase 1 / Phase 2 | Recruiting | Brigham and Women's Hospital | 24 | 2026-09-01 | 2026-09-21 |
| Post-Operative Steroids After Sleep Surgery 8mg dexamethasone - Obstructive Sleep Apnea | Phase 2 | Withdrawn | Medical University of South Carolina | 2026-07-01 | 2026-10-06 | |
| DRonabinol Treatment of OSA Dronabinol - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Recruiting | VA Office of Research and Development | 120 | 2025-08-25 | 2026-11-05 |
| A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension Lorundrostat, Placebo - Obstructive Sleep Apnea, Hypertension | Phase 2 | Completed | Mineralys Therapeutics Inc. | 48 | 2025-02-28 | 2026-08-21 |
| Impact of Exogenous Ketones on Sleep Apnea Ketone-IQ, Placebo - Obstructive Sleep Apnea, Sleep | Phase 1 / Phase 2 | Withdrawn | Johns Hopkins University | 2025-01-29 | 2026-09-21 | |
| RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA IHL-42X Low Dose, IHL-42X High Dose, Placebo - Obstructive Sleep Apnea | Phase 2 / Phase 3 | Completed | Incannex Healthcare Ltd | 121 | 2024-05-02 | 2026-07-27 |
| The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome) bi-level positive pressure non invasive ventilation, Oxygen gas - Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease | Phase 2 | Recruiting | University of California, San Diego | 240 | 2024-02-13 | 2026-06-03 |
| Endotypic Traits and Obstructive Sleep Apnea Surgery Acetazolamide 500 MG QHS, Eszopiclone 3 mg QHS - Obstructive Sleep Apnea | Phase 2 | Recruiting | University of California, Los Angeles | 150 | 2024-01-07 | 2026-07-01 |
| Phototherapy for Non-responders to Oral Appliance Therapy for Obstructive Sleep Apnea Phototherapy - Obstructive Sleep Apnea | Phase 2 | Recruiting | University of Alberta | 528 | 2024-01-05 | 2026-06-01 |
| Trazodone on OSA Endotypes Placebo oral tablet, Trazodone Hydrochloride - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Recruiting | Brigham and Women's Hospital | 18 | 2024-01-01 | 2025-02-06 |
| Down Syndrome Obstructive Sleep Apnea Oxygen - Down Syndrome, Obstructive Sleep Apnea | Phase 2 | Recruiting | Brigham and Women's Hospital | 230 | 2023-10-24 | 2026-09-30 |
| Managing Opioid Related Sleep Apnea With Acetazolamide Acetazolamide, Placebo - Sleep-Disordered Breathing, Obstructive Sleep Apnea | Phase 2 | Completed | University of California, San Diego | 39 | 2023-10-18 | 2026-03-10 |
| Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome Atomoxetine and Oxybutynin (ato-oxy) - Obstructive Sleep Apnea, Down Syndrome | Phase 2 | Active not recruiting | University of Arizona | 36 | 2023-09-29 | 2026-04-07 |
| Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP) Eszopiclone 2 mg, Placebo - Obstructive Sleep Apnea | Phase 2 | Completed | University of California, San Diego | 42 | 2023-08-31 | 2025-11-25 |
| Rescue Pharmacotherapy for OSA Placebo, Acetazolamide, Trazodone - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Recruiting | Brigham and Women's Hospital | 70 | 2023-07-01 | 2026-07-15 |
| Patient-centered and Neurocognitive Outcomes With Acetazolamide for Sleep Apnea Acetazolamide, Placebo - Obstructive Sleep Apnea | Phase 2 | Recruiting | University of California, San Diego | 60 | 2023-05-16 | 2026-05-08 |
| AD816 Crossover Study Period A, Period B, Period C - OSA, Obstructive Sleep Apnea | Phase 2 | Completed | Apnimed | 25 | 2023-04-28 | 2023-11-15 |
| Acetazolamide on REM OSA Placebo oral capsule, Acetazolamide - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Completed | Brigham and Women's Hospital | 11 | 2023-01-30 | 2026-01-20 |
| Intermittent Hypoxia-initiated Plasticity in Humans: A Multi-pronged Therapeutic Approach to Treat Sleep Apnea and Overlapping Co-morbidities Mild Intermittent Hypoxia, Sham MIH - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Recruiting | VA Office of Research and Development | 60 | 2023-01-01 | 2025-12-04 |
Showing 20 of 72. Sign in to see all of them.
Sleep Apnea, Obstructive (72) · Sleep Apnea Syndromes (18) · Hypertension (7) · Sleep Wake Disorders (5) · Down Syndrome (3) · Obesity (3) · Pain (3) · Stroke (3) · Apnea (2) · Cardiovascular Diseases (2) · Chronic Pain (2) · Respiration Disorders (2) · Tonsillitis (2) · Behavior (1) · Brain Ischemia (1)
Dyssomnias (72) · Nervous System Diseases (72) · Respiratory Tract Diseases (72) · Sleep Disorders, Intrinsic (72) · Apnea (70) · Respiration Disorders (70) · Sleep Wake Disorders (67) · Sleep Apnea Syndromes (54) · Pathological Conditions, Signs and Symptoms (14) · Signs and Symptoms (12) · Neurologic Manifestations (11) · Vascular Diseases (9) · Cardiovascular Diseases (8) · Mental Disorders (6) · Nutritional and Metabolic Diseases (6)
Continuous Positive Airway Pressure (11) · Acetazolamide (9) · Atomoxetine Hydrochloride (9) · Eszopiclone (5) · Dronabinol (3) · Occlusal Splints (3) · oxybutynin (3) · Dexmedetomidine (2) · Oxygen (2) · Trazodone (2) · (Lys-Gly)(5)cyclo(75-82)MBP(74-85) (1) · Adrenergic beta-Antagonists (1) · Bosentan (1) · Calcium Dobesilate (1) · Celecoxib (1)
Brigham and Women's Hospital (12) · Apnimed (8) · University of California, San Diego (8) · Johns Hopkins University (3) · University of Michigan (3) · VA Office of Research and Development (3) · Apnex Medical, Inc. (2) · Duke University (2) · Göteborg University (2) · University of Arizona (2) · All India Institute of Medical Sciences (1) · Associação Fundo de Incentivo à Pesquisa (1) · Desitin Arzneimittel GmbH (1) · Erin Kirkham (1) · Hubei Hospital of Traditional Chinese Medicine (1)
United States (53) · Australia (2) · Canada (2) · Sweden (2) · Belgium (1) · Brazil (1) · China (1) · Denmark (1) · France (1) · India (1) · Israel (1) · Italy (1) · Netherlands (1) · Singapore (1)
Scott A Sands, PhD (3) · Atul Malhotra, MD (2) · Christopher N Schmickl, MD, PhD (2) · Christopher Schmickl, MD, PhD (2) · Jan Hedner, MD. Prof. (2) · Jeremy Orr, MD (2) · Ron Farkas, MD (2) · Alan R Schwartz, M.D. (1) · Beth Malow, M.D., M.S. (1) · Bharati Prasad, MD (1) · Bradley A Edwards, PhD (1) · Brian Colin, MD (1) · Bruce Corser, MD (1) · Carol Rosen, M.D. (1) · Christopher E Kline, MS (1)
PMID 18513353, PMID 18711110, PMID 21784661, PMID 21885958, PMID 22043118, PMID 22131599, PMID 22334806, PMID 22547887, PMID 22572632, PMID 22893765, PMID 22968110, PMID 24458967, PMID 24815497, PMID 24918372, PMID 25892349, PMID 26643404, PMID 29035093, PMID 29510792, PMID 29800466, PMID 32649638, PMID 34225174, PMID 34543665, PMID 35551600, PMID 35975547, PMID 36494591, PMID 36734173, PMID 36805833, PMID 37555595, PMID 37938917, PMID 38507976, PMID 38669011, PMID 39305436, PMID 39514000, PMID 39688178, PMID 40158847, PMID 40360261, PMID 40705710, PMID 41077049, PMID 41424523, PMID 41781273, PMID 41811641
K23HL151880 (2), 2009 (1), 2015 (1), 2019 (1), I01CX002632 (1), K23HL153897 (1), K23HL161336 (1), R01HL106410 (1), R01HL128658 (1), R01HL160993 (1), R01NS042698 (1), R03HL138068 (1), R33HL151254 (1), R61HL151254 (1), UL1RR024989 (1)